Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic hepatitis B
Biotech
Aligos sells China rights to HBV drug in $445M deal
Aligos has secured a $25 million upfront fee from hepatology biopharma Amoytop for the China rights to its phase 2-stage HBV treatment.
James Waldron
Apr 16, 2026 9:12am
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
May 22, 2025 10:10am
Vir's hep B program fails to hit efficacy mark in phase 2
May 9, 2025 9:35am
Arbutus jettisons 57% of staff, ends in-house research
Mar 27, 2025 11:11am
GSK drops 1 potential 'cure' for hep B, focuses on bepirovirsen
Feb 5, 2025 6:00am
